首页> 外文期刊>International Orthopaedics >Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck Disease (KBD) patients
【24h】

Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck Disease (KBD) patients

机译:塞来昔布,美洛昔康和扑热息痛对老年Kashin-Beck病(KBD)患者的疗效

获取原文
获取原文并翻译 | 示例
       

摘要

The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.
机译:这项研究的目的是比较塞来昔布,美洛昔康和扑热息痛在晚期卡欣-贝克病中的疗效和耐受性。患有Kashin-Beck病的成人(n = 168)被随机分组​​,接受六周疗程的塞来昔布200 mg每天一次,美洛昔康7.5 mg每天一次或扑热息痛300 mg每天3次。疗效评估包括总体关节疼痛强度以及西安大略省和麦克马斯特大学骨关节炎指数子量表;通过不良事件和医生报告评估耐受性。塞来昔布和美洛昔康可有效缓解疼痛并改善僵硬,但六周后无法改善其身体机能。扑热息痛可有效缓解疼痛,但六周后无法改善晨僵和身体机能。塞来昔布和美洛昔康可提供可预期且持续的疼痛和僵硬缓解。扑热息痛可以缓解疼痛。在Kashin-Beck病中,没有一种疗法能改善身体功能受损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号